ID: ALA2414011

Max Phase: Preclinical

Molecular Formula: C29H46O4

Molecular Weight: 458.68

Molecule Type: Small molecule

Representations

Canonical SMILES:  C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C2(COC2)[C@@H]1O

Standard InChI:  InChI=1S/C29H46O4/c1-19(8-6-14-27(3,4)32)23-12-13-24-21(9-7-15-28(23,24)5)10-11-22-16-25(30)29(17-33-18-29)26(31)20(22)2/h10-11,19,23-26,30-32H,2,6-9,12-18H2,1,3-5H3/b21-10+,22-11-/t19-,23-,24+,25-,26-,28-/m1/s1

Standard InChI Key:  LCHVWSUKWYYMBB-YVOASEAMSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 458.68

Molecular Weight (Monoisotopic): 458.3396

AlogP: 5.33

#Rotatable Bonds: 6

Polar Surface Area: 69.92

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.76

CX Basic pKa:

CX LogP: 3.92

CX LogD: 3.92

Aromatic Rings: 0

Heavy Atoms: 33

QED Weighted: 0.50

Np Likeness Score: 2.34

References

1. Fujishima T, Nozaki T, Suenaga T..  (2013)  Design and synthesis of novel 1,25-dihydroxyvitamin D3 analogues having a spiro-oxetane fused at the C2 position in the A-ring.,  21  (17): [PMID:23845283] [10.1016/j.bmc.2013.06.032]

Source

Source(1):

• Scientific Literature